SANGUINATE™(PEGylated Carboxyhemoglobin Bovine) improves cerebral blood flow to vulnerable brain regions at risk of delayed cerebral ischemia after …
R Dhar, H Misra, MN Diringer - Neurocritical Care, 2017 - Springer
Background Delayed cerebral ischemia (DCI) after subarachnoid hemorrhage (SAH) has
been linked to focal reductions in cerebral blood flow (CBF) and microvascular impairments
in oxygen delivery. Effective therapies that restore flow and oxygen transport to vulnerable
brain regions are currently lacking. SANGUINATE is a dual-action carbon monoxide-
releasing and hemoglobin-based oxygen transfer agent with efficacy in animal models of
focal brain ischemia and tolerability in patients with sickle cell disease. Methods We …
been linked to focal reductions in cerebral blood flow (CBF) and microvascular impairments
in oxygen delivery. Effective therapies that restore flow and oxygen transport to vulnerable
brain regions are currently lacking. SANGUINATE is a dual-action carbon monoxide-
releasing and hemoglobin-based oxygen transfer agent with efficacy in animal models of
focal brain ischemia and tolerability in patients with sickle cell disease. Methods We …
Sanguinate (PEGylated-carboxyhemoglobin-bovine) Improves Cerebral Blood Flow and Oxygen Extraction to Vulnerable Brain Regions in Patients at Risk for …
R Dhar, H Misra, M Diringer - Stroke, 2017 - Am Heart Assoc
Introduction: Sanguinate is a dual-action oxygen transfer and carbon monoxide-releasing
agent with efficacy in animal models of focal brain ischemia and established safety in health
volunteers. We performed a dose-escalation study in subarachnoid hemorrhage (SAH)
patients at risk for delayed cerebral ischemia (DCI) to evaluate tolerability and explore
efficacy in improving cerebral blood flow (CBF) and flow-metabolism balance to vulnerable
brain regions. Methods: 12 subjects were studied over three dose tiers: 160mg/kg, 240 …
agent with efficacy in animal models of focal brain ischemia and established safety in health
volunteers. We performed a dose-escalation study in subarachnoid hemorrhage (SAH)
patients at risk for delayed cerebral ischemia (DCI) to evaluate tolerability and explore
efficacy in improving cerebral blood flow (CBF) and flow-metabolism balance to vulnerable
brain regions. Methods: 12 subjects were studied over three dose tiers: 160mg/kg, 240 …
